Welcome to our dedicated page for Sintx Technologies news (Ticker: SINT), a resource for investors and traders seeking the latest updates and insights on Sintx Technologies stock.
SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics and biomaterials company headquartered in Salt Lake City, Utah, with news flow centered on silicon nitride–based medical technologies, implant systems, and infection‑prevention platforms. This news page aggregates company press releases and third‑party coverage so readers can follow developments in its silicon nitride biomaterials, polymer composites, and antipathogenic fabric technologies.
Recent SINTX news highlights regulatory milestones and product launches, including U.S. FDA 510(k) clearance for the SINAPTIC Foot & Ankle Osteotomy Wedge System and the launch of OsseoSculpt, a biologic designed to complement the SINAPTIC wedge portfolio. Updates also cover the company’s focused commercialization plan around infection‑resistant silicon nitride devices and polymer composites, as well as early product revenue from OsseoSculpt.
Investors and industry observers will find coverage of strategic agreements, such as the supply agreement with EVONIK to manufacture SINTX’s proprietary SiN/PEEK compound for AI‑assisted, 3D‑printed, patient‑specific implants. News items also track SINTX’s intellectual‑property progress, including Notices of Allowance from the United States Patent and Trademark Office for composition and method patents covering antipathogenic fibrous materials and fabric technologies.
In addition, SINTX issues releases on capital markets activity and corporate events, including warrant exercises, at‑the‑market offering arrangements, and participation in investor conferences hosted by firms such as H.C. Wainwright and Sidoti & Company. These updates provide context on the company’s financing strategy and investor outreach.
By monitoring this page, readers can review SINTX news related to medical device clearances, biologic product introductions, infection‑prevention patents, financing transactions, and investor presentations, all in one place.
SINTX Technologies, Inc. (NASDAQ: SINT) announced the closing of a registered direct offering of 3,415,000 shares at $2.40 per share, raising gross proceeds of $8.2 million. The shares were offered under a previously filed shelf registration statement. Maxim Group LLC served as the sole placement agent. The proceeds will be allocated for general working capital and corporate purposes. SINTX specializes in the production of silicon nitride ceramics for medical applications, with its manufacturing facility FDA registered and ISO certified.
SINTX Technologies has entered into a share purchase agreement to issue 3,415,000 shares at $2.40 each, generating approximately $8.2 million. This registered direct offering is priced at-the-market under Nasdaq rules and is expected to close on August 7, 2020, pending customary closing conditions. Maxim Group LLC is the sole placement agent for this offering, which is conducted under a previously filed Form S-3 registration statement.
The shares will be offered via a supplement to the existing prospectus filed with the SEC.
SINTX Technologies, Inc. (NASDAQ: SINT) has announced a registered direct offering involving the sale of 1,500,000 shares of common stock at $2.00 per share for gross proceeds of approximately $3.0 million. The offering is set to close around July 21, 2020, contingent on customary conditions. Maxim Group LLC is acting as the sole placement agent. The shares are offered under an effective shelf registration statement filed with the SEC. The funds are expected to support the company's operations and development of silicon nitride ceramics for various applications.
SINTX Technologies has announced its compliance with NASDAQ's minimum bid price requirements for continued listing. This follows a notice from NASDAQ indicating that SINTX's common stock closed at or above $1.00 for at least ten consecutive business days, from June 22 to July 8, 2020. The matter concerning Listing Rule 5550(a)(2) is now resolved. SINTX focuses on manufacturing and developing silicon nitride ceramics for various applications, bolstered by its FDA-registered and ISO 13485 certified facility.
SINTX Technologies, Inc. (NASDAQ: SINT) announced a registered direct offering of 3,700,000 shares at $1.50 each, raising approximately $5.6 million. The offering is set to close around June 25, 2020, pending customary conditions. Maxim Group LLC is the sole placement agent. This issuance is part of a previously filed shelf registration statement under SEC rules. The funds raised will likely support SINTX's ongoing development of silicon nitride applications in various sectors.
SINTX Technologies (NASDAQ: SINT) announced promising preliminary results from a controlled study showing that their sintered silicon nitride powder inactivates the SARS-CoV-2 virus. The findings align with known antibacterial properties of silicon nitride and efficacy against similar viruses. CEO Dr. Sonny Bal emphasized ongoing independent testing to validate these results. SINTX is dedicated to rigorous R&D verification. However, they caution investors against assuming commercial effectiveness until further data is available.